R. Fleck

发表

The discovery of thienopyridine analogues as potent IkappaB kinase beta inhibitors. Part II.

M. Hao, C. Cywin, E. Hickey, 2009, Bioorganic & medicinal chemistry letters.

Substituted pyrazoles as novel sEH antagonist: investigation of key binding interactions within the catalytic domain.

J. Proudfoot, U. Patel, Rajiv Sharma, 2010, Bioorganic & medicinal chemistry letters.

Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T‐cell lymphoma

C. Pirker, W. Berger, L. Cerroni, 2022, EMBO molecular medicine.

2-Aminobenzimidazoles as potent ITK antagonists: trans-stilbene-like moieties targeting the kinase specificity pocket.

J. Woska, M. Kashem, Hidenori Takahashi, 2008, Bioorganic & medicinal chemistry letters.

STAT5 Gain-of-Function Variants Promote Precursor T-Cell Receptor Activation to Drive T-Cell Acute Lymphoblastic Leukemia

T. Aittokallio, S. Mustjoki, T. Haferlach, 2022, bioRxiv.

2-Trifluoroacetyl aminoindoles as useful intermediates for the preparation of 2-acylamino indoles

G. Roth, Hidenori Takahashi, F. Camara, 2011 .

Catalytic antibodies induced by a zwitterionic hapten.

T. Tsumuraya, S. Masamune, R. Fleck, 2001, Chemistry.

Trends in Personalized Therapies in Oncology: The (Venture) Capitalist’s Perspective

Daniel Q. Bach, R. Fleck, 2012, Journal of personalized medicine.

Design and syntheses of three haptens to generate catalytic antibodies that cleave amide bonds with nucleophilic catalysis.

M. Blanco, S. Masamune, R. Fleck, 1999, Bioorganic & medicinal chemistry.